NATCO Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.04×	0.95×	0.82×	0.83×	0.83×
	1.29×	1.21×	1.17×	1.07×	1.12×
	24.6%	30.2%	44.3%	39.1%	28.5%
	0.41×	0.41×	0.57×	0.64×	0.50×
	1.20×	1.20×	1.13×	1.18×	1.16×
	16.2%	17.1%	27.5%	26.2%	15.3%
	16.9%	16.9%	28.0%	25.9%	15.7%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NATCOPHARM₹787.55

NATCO Pharma Ltd.

· Pharma & Health

₹ CrorePeersDRREDDY ZYDUSLIFE SUNPHARMA LALPATHLAB NEULANDLAB NH SAILIFE COHANCEMcap ₹14,097 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.83	0.83	0.82	0.95	1.04
Interest Burden (Pretax/EBIT) ×	1.12	1.07	1.17	1.21	1.29
EBIT Margin %	28.51	39.13	44.27	30.16	24.56
Asset Turnover ×	0.50	0.64	0.57	0.41	0.41
Financial Leverage (Assets/Equity) ×	1.16	1.18	1.13	1.20	1.20
ROE (5-step product, year-end total equity) %	15.34	26.22	27.48	17.13	16.17
ROE (owners' profit / average owners' equity) %	15.66	25.88	28.01	16.86	16.86

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.